Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary disorders
- Focus Diagnostic use
- 15 May 2019 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 20 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed to 1 Aug 2020.